

# Olaf Neumann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8466528/publications.pdf>

Version: 2024-02-01

26  
papers

1,388  
citations

516215

16  
h-index

552369

26  
g-index

26  
all docs

26  
docs citations

26  
times ranked

2496  
citing authors

#	ARTICLE	IF	CITATIONS
1	Accurate and efficient detection of gene fusions from RNA sequencing data. <i>Genome Research</i> , 2021, 31, 448-460.	2.4	215
2	Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians. <i>Translational Lung Cancer Research</i> , 2018, 7, 703-715.	1.3	152
3	Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. <i>Hepatology</i> , 2012, 56, 1817-1827.	3.6	136
4	Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. <i>International Journal of Cancer</i> , 2019, 144, 848-858.	2.3	131
5	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. <i>Cancer Discovery</i> , 2021, 11, 2780-2795.	7.7	125
6	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: <i>in silico</i> and real-life analysis of three larger gene panels. <i>International Journal of Cancer</i> , 2019, 144, 2303-2312.	2.3	95
7	Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. <i>International Journal of Cancer</i> , 2019, 145, 649-661.	2.3	85
8	Variant classification in precision oncology. <i>International Journal of Cancer</i> , 2019, 145, 2996-3010.	2.3	76
9	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1935-1947.	0.5	69
10	Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival. <i>Cancers</i> , 2019, 11, 124.	1.7	36
11	Protumorigenic role of Timeless in hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2015, 46, 597-606.	1.4	32
12	RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. <i>Cancers</i> , 2019, 11, 1309.	1.7	32
13	Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. <i>International Journal of Cancer</i> , 2019, 145, 2963-2973.	2.3	24
14	Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD). <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	23
15	Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis. <i>Gut</i> , 2022, 71, 391-401.	6.1	21
16	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	1.5	20
17	Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. <i>Oncogene</i> , 2020, 39, 814-832.	2.6	19
18	Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 303-313.	1.5	15

#	ARTICLE	IF	CITATIONS
19	Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 3-11.	1.5	14
20	Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. <i>International Journal of Cancer</i> , 2020, 146, 3053-3064.	2.3	14
21	Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. <i>European Journal of Cancer</i> , 2021, 157, 179-189.	1.3	13
22	High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer – Results from a prospective pilot study using a 37 gene panel. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 637.e17-637.e27.	0.8	12
23	Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 406-416.	1.5	10
24	Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field. <i>Lung Cancer</i> , 2021, 154, 131-141.	0.9	8
25	Primary pulmonary myxoid sarcoma with an unusual gene fusion between exon 7 of EWSR1 and exon 5 of CREB1. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 787-791.	1.4	7
26	Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 551-560.	1.5	4